Phase II study of Combination Therapy of Pemetrexed/Carboplatin/Bevacizumab for Advanced Non-small-cell lung cancer
Phase 2
Recruiting
- Conditions
- non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000004685
- Lead Sponsor
- ational Hospital Organization Hokkaido Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1)Uncontrolled complication unstable angina or myocardiac infarction within 3 months uncontrolled DM and hypertension uncontrolled infection active interstitial pneumonia active gastiric ulcer active concominant cancer illeus 2)patients who cannot been given Bevacizumab with great vessel invasion cavity in tumor current or previous histoty ofhemoptysis(2.5ml)due to NSCLC receiving anticoagulant drug(except Aspirin under 325mg/day) untreated current brain metastasis 3)history of sever allergy 4)severe SVC syndrome 5)uncontrolled malignant pleuritis 6)history of pregnancy or lactation 7)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method